CETYLEV Drug Patent Profile
✉ Email this page to a colleague
When do Cetylev patents expire, and when can generic versions of Cetylev launch?
Cetylev is a drug marketed by Arbor Pharms Llc and is included in one NDA. There are three patents protecting this drug.
This drug has one patent family member in one country.
The generic ingredient in CETYLEV is acetylcysteine. There are three drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the acetylcysteine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cetylev
A generic version of CETYLEV was approved as acetylcysteine by HOSPIRA on August 30th, 1994.
Summary for CETYLEV
| International Patents: | 1 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 156 |
| Clinical Trials: | 1 |
| Patent Applications: | 3,758 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CETYLEV |
| DailyMed Link: | CETYLEV at DailyMed |
Recent Clinical Trials for CETYLEV
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Maryland, Baltimore | Phase 1/Phase 2 |
| University of Maryland | Phase 1/Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for CETYLEV
US Patents and Regulatory Information for CETYLEV
CETYLEV is protected by three US patents.
Patents protecting CETYLEV
Effervescent compositions containing N-acetylcysteine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS
Effervescent compositions containing N-acetylcysteine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Effervescent compositions containing N-acetylcysteine
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arbor Pharms Llc | CETYLEV | acetylcysteine | TABLET, EFFERVESCENT;ORAL | 207916-002 | Jan 29, 2016 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Arbor Pharms Llc | CETYLEV | acetylcysteine | TABLET, EFFERVESCENT;ORAL | 207916-001 | Jan 29, 2016 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Arbor Pharms Llc | CETYLEV | acetylcysteine | TABLET, EFFERVESCENT;ORAL | 207916-002 | Jan 29, 2016 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Arbor Pharms Llc | CETYLEV | acetylcysteine | TABLET, EFFERVESCENT;ORAL | 207916-002 | Jan 29, 2016 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Arbor Pharms Llc | CETYLEV | acetylcysteine | TABLET, EFFERVESCENT;ORAL | 207916-001 | Jan 29, 2016 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Arbor Pharms Llc | CETYLEV | acetylcysteine | TABLET, EFFERVESCENT;ORAL | 207916-001 | Jan 29, 2016 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CETYLEV
See the table below for patents covering CETYLEV around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 2662077 | COMPOSITION EFFERVESCENTE CONTENANT DE LA N-ACÉTYL-CYSTÉINE (EFFERVESCENT COMPOSITIONS CONTAINING N-ACETYLCYSTEINE) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
